# DEA Synthetic Opioid Scheduling Updates March 2026 > **Author:** Benjamin Caplan, MD (ABFM Board Certified, MA Lic. #240562, NPI: 1962722637) > **Publisher:** CED Clinic (https://cedclinic.com) > **Canonical URL:** https://cedclinic.com/dea-synthetic-opioid-scheduling-updates-march-2026/ > **Published:** 2026-03-19T14:07:56-04:00 | **Last Modified / Clinically Audited:** 2026-09-28T11:05:09-04:00 > **Clinical Summary:** Explore the latest DEA synthetic opioid scheduling regulatory updates for March 2026 and their implications for clinical practice and cannabis clinicians. --- Policy WatchMarch 19, 2026. 10 regulatory items above the clinical relevance threshold of 40. Sources include Federal Register, regulations.gov, and regulatory RSS feeds. Listed in descending order of relevance score. Score 70Regulations.gov [Schedules of Controlled Substances: Placement of Butonitazene, Flunitazene, and Metodesnitazene in Schedule I](https://www.regulations.gov/document/DEA-2021-0031-0011) Regulatory Action Summary This DEA action schedules three synthetic opioids (butonitazene, flunitazene, metodesnitazene) as Schedule I controlled substances, with no direct impact on cannabis regulation or [clinical cannabis](https://cedclinic.com/entourage-effect-cannabis-clinical-breeding-benefits/) practice. [Read more →](https://www.regulations.gov/document/DEA-2021-0031-0011) Score 70Regulations.gov [Schedules of Controlled Substances: Placement of Ethylphenidate in Schedule I](https://www.regulations.gov/document/DEA-2023-0129-0013) Regulatory Summary This action schedules ethylphenidate as a controlled substance, which is relevant to cannabis clinicians managing patients with ADHD who may use cannabis and require awareness of potential drug interactions and [alternative treatment](https://cedclinic.com/cannabinoids-pain-management-opioid-alternative/) considerations. [Read more →](https://www.regulations.gov/document/DEA-2023-0129-0013) Score 70Regulations.gov [Schedules of Controlled Substances: Temporary Placement of N-pyrrolidino metonitazene and N-pyrrolidino protonitazene in Schedule I](https://www.regulations.gov/document/DEA-2024-0118-0001) This regulation temporarily places two synthetic opioids in Schedule I; it does not directly affect [cannabis medicine](https://cedclinic.com/essential-oils-industrial-hemp-antimicrobial-benefits/) but may be relevant to clinicians treating patients with concurrent opioid use disorders. [Read more →](https://www.regulations.gov/document/DEA-2024-0118-0001) Score 70Regulations.gov [Importer of Controlled-Biopharmaceutical(2024-20085)DEA1425](https://www.regulations.gov/document/DEA-2024-0112-0001) Regulatory Summary This DEA registration allows importation of controlled biopharmaceuticals, potentially enabling cannabis clinicians to access federally regulated cannabis-derived medicines for research, clinical use, or patient treatment protocols. [Read more →](https://www.regulations.gov/document/DEA-2024-0112-0001) Score 70Regulations.gov [Schedules of Controlled Substances: Temporary Placement of N-Desethyl Isotonitazene and N-Piperidinyl Etonitazene in Schedule I](https://www.regulations.gov/document/DEA-2023-0147-0003) Regulatory Summary This action schedules synthetic opioids under DEA Schedule I but does not directly affect cannabis medical practice, as these substances are distinct from cannabis and its cannabinoid derivatives. [Read more →](https://www.regulations.gov/document/DEA-2023-0147-0003) Score 70Regulations.gov [Schedules of Controlled Substances: Rescheduling of Marijuana](https://www.regulations.gov/document/DEA-2024-0059-0001) Regulatory Summary The DEA proposed rescheduling marijuana from Schedule I to Schedule III, potentially enabling increased research access and allowing qualified healthcare providers to prescribe cannabis-based medications under federal law. [Read more →](https://www.regulations.gov/document/DEA-2024-0059-0001) Score 70Regulations.gov [Definition of Engaged in the Business as a Dealer in Firearms](https://www.regulations.gov/document/ATF_FRDOC_0001-0052) Regulatory Item Summary This firearms dealer definition regulation has no direct relevance to cannabis clinicians or patients, as it pertains exclusively to federal firearm commerce regulation under the Bureau of Alcohol, Tobacco, Firearms and Explosives (ATF). [Read more →](https://www.regulations.gov/document/ATF_FRDOC_0001-0052) Score 70Regulations.gov [Schedules of Controlled Substances: Placement of Etodesnitazene, N-Pyrrolidino etonitazene, and Protonitazene in Schedule I](https://www.regulations.gov/document/DEA-2021-0031-0006) Regulatory Summary This DEA action schedules three opioid-like synthetic compounds as Schedule I controlled substances, with no direct regulatory impact on [cannabis medicine](https://cedclinic.com/essential-oils-industrial-hemp-antimicrobial-benefits/), clinicians, or patients. [Read more →](https://www.regulations.gov/document/DEA-2021-0031-0006) Score 70Regulations.gov [Schedules of Controlled Substances: Placement of Butonitazene, Flunitazene, and Metodesnitazene Substances in Schedule I](https://www.regulations.gov/document/DEA-2021-0031-0007) This regulation schedules three opioid analogs as Schedule I substances, having no direct relevance to cannabis clinicians or patients as it addresses separate controlled substances outside cannabis medicine practice. [Read more →](https://www.regulations.gov/document/DEA-2021-0031-0007) Score 70Regulations.gov [Schedules of Controlled Substances: Placement of 2-Methyl AP-237 in Schedule I](https://www.regulations.gov/document/DEA-2024-0026-0001) Regulatory Summary The DEA placed synthetic opioid 2-Methyl AP-237 in Schedule I, establishing it as a controlled substance with no medical use—relevant to cannabis clinicians considering alternative [pain management](https://cedclinic.com/cbd-cbg-topicals-for-eczema/) strategies for patients. [Read more →](https://www.regulations.gov/document/DEA-2024-0026-0001) Digest-Level Clinical Commentary Dr. Caplan’s Take The rescheduling of marijuana signals a significant shift in federal cannabis policy that will likely expand research opportunities and clinical legitimacy for cannabis medicine, though the remaining items reflect the DEA’s continued focus on synthetic opioid analogues rather than cannabis itself. This development suggests that future practice will require updated clinical protocols, enhanced patient education regarding evidence-based applications, and closer attention to evolving regulatory frameworks that may finally permit the rigorous pharmacological studies our field has long needed. As practitioners, we should anticipate increased patient inquiries and insurance coverage discussions while remaining cautious about therapeutic claims until robust clinical evidence emerges from federally-enabled research programs. Clinical Perspective Cannabis-Related Items Digest – Clinical Perspective The predominance of Schedule I placements for novel synthetic opioids reflects ongoing regulatory responses to emerging drugs of abuse that are appearing in illicit drug supplies and causing clinical harm. While most items address nitazene analogs and related synthetic compounds rather than cannabis specifically, the single cannabis rescheduling item represents a significant shift in drug policy that has substantial implications for clinical practice, research availability, and patient access to treatment options. These regulatory actions demonstrate the DEA’s continuous monitoring and classification efforts to address the evolving landscape of controlled substances, though clinicians should note that scheduling changes alone do not directly modify evidence-based treatment protocols or clinical decision-making in most practice settings. Controlled SubstancesDrug SchedulingDEA RegulationsCannabis Policy 💬 Join the Conversation Have a question about how this applies to your situation? [Ask Dr. Caplan →](https://benjamincaplan.com/ask-dr-caplan) Want to discuss this topic with other patients and caregivers? [Join the forum discussion →](https://cedclinic.com/interact/discussion-forums/forum/ask-dr-caplan/) Have thoughts on this? Share it: [𝕏 Share on X](https://twitter.com/intent/tweet?text=Just+read+this+on+CEDclinic.com%3A+Policy+Watch+%E2%80%94+March+19%2C+2026+%40drcaplan&url=)[in Share on LinkedIn](https://www.linkedin.com/sharing/share-offsite/?url=)[🦅 Share on BlueSky](https://bsky.app/intent/compose?text=Just+read+this%3A+Policy+Watch+%E2%80%94+March+19%2C+2026+--+via+%40drcaplan.bsky.social+)[📷 Follow on Instagram](https://www.instagram.com/drbenjamincaplan/)[📝 Read more on Substack](https://substack.com/@doctorapproved)[🔔 Subscribe via RSS](https://cedclinic.com/category/cannabis-news/feed/) Related Articles - [High Marijuana Taxes Don’t Effectively Deter Use, Study Shows, Contrary To NYT Editorial …](https://cedclinic.com/cannabis-tax-increases-patient-use-study-insights/) - [DEA admits legal cannabis isn’t increasing youth use (Newsletter: March 19, 2026)](https://cedclinic.com/legal-cannabis-youth-use-data-no-increase/) - [Drug legalization: Basel-Stadt takes positive stock after three years of cannabis dispensing](https://cedclinic.com/basel-stadt-cannabis-dispensing-program/) [https://cedclinic.com/contact/](https://cedclinic.com/contact/) Physician-Led, Whole-Person Care A doctor who takes the time to truly understand you. Personal care that starts with listening and is guided by experience and ingenuity. Health, Longevity, Wellness One-on-One Cannabis Guidance Metabolic Balance [Leave a Message](https://cedclinic.com/contact/) [Metabolic Care](https://cedclinic.com/metabolic/metabolic-how-it-works/) [Medical Consulting](https://cedclinic.com/book/) [Cannabis Care](https://cedclinic.com/book/) [https://cedclinic.com/contact/](https://cedclinic.com/contact/) RELATED READING AT CED CLINIC Continue exploring the evidence [Policy Watch: 10 Regulatory Updates — March 18, 2026](https://cedclinic.com/dea-marijuana-rescheduling-2026-regulatory-updates/) Review the previous day's regulatory updates focusing on controlled substances and cannabis policy changes. [Read March 18 Updates](https://cedclinic.com/dea-marijuana-rescheduling-2026-regulatory-updates/) [Policy Watch: 20 Regulatory Updates — March 12, 2026](https://cedclinic.com/cannabis-regulatory-updates-march-2026/) A comprehensive overview of regulatory changes affecting cannabis and controlled substances earlier in March 2026. [Explore March 12 Updates](https://cedclinic.com/cannabis-regulatory-updates-march-2026/) [Policy Watch: 27 Regulatory Updates — March 16, 2026](https://cedclinic.com/dea-temporary-schedule-i-placement-march-16-2026/) Detailed insights into mid-March regulatory actions impacting cannabis clinical practice and controlled substances. [View March 16 Updates](https://cedclinic.com/dea-temporary-schedule-i-placement-march-16-2026/) ### Related --- ### Verification & Medical Governance - **Lead Clinical Author:** Benjamin Caplan, MD - **Credentials:** Board Certified in Family Medicine (ABFM), Founder & CMO CED Clinic & CED Foundation, Author of *The Doctor-Approved Cannabis Handbook* (Penguin Random House). - **Clinical Scale:** 350,000+ lifetime evaluations overseen; 81,008-patient Real-World Evidence Registry (`~/.ced_rwe_vault.db`); 125,000+ peer-reviewed study literature observatory (`http://localhost:8768/api/explorer/terminal`). - **License Verification:** Commonwealth of Massachusetts License #240562 (https://checkahealthlicense.mass.gov/). - **NPI Registry:** 1962722637 (https://npiregistry.cms.hhs.gov/provider-view/1962722637). - **Ethics & Data Privacy:** Clinical registry observations adhere strictly to HIPAA Safe Harbor de-identification (45 CFR § 164.514(b)) and criteria for secondary research exemption under 45 CFR § 46.104(d)(4).